

DYRK2 Antibody (N-term)

Purified Rabbit Polyclonal Antibody (Pab) Catalog # AP7534a

Specification

DYRK2 Antibody (N-term) - Product Information

Application
Primary Accession
Reactivity
Host
Clonality
Isotype
Antigen Region

WB, IHC-P,E
O92630
Human
Rabbit
Polyclonal
Rabbit IgG
Antigen Region

DYRK2 Antibody (N-term) - Additional Information

Gene ID 8445

Other Names

Dual specificity tyrosine-phosphorylation-regulated kinase 2, DYRK2

Target/Specificity

This DYRK2 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 105-135 amino acids from the N-terminal region of human DYRK2.

Dilution

WB~~1:1000 IHC-P~~1:50~100

Format

Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.

Storage

Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.

Precautions

DYRK2 Antibody (N-term) is for research use only and not for use in diagnostic or therapeutic procedures.

DYRK2 Antibody (N-term) - Protein Information

Name DYRK2

Function Serine/threonine-protein kinase involved in the regulation of the mitotic cell cycle, cell proliferation, apoptosis, organization of the cytoskeleton and neurite outgrowth. Functions in part via its role in ubiquitin-dependent proteasomal protein degradation. Functions downstream of ATM



and phosphorylates p53/TP53 at 'Ser-46', and thereby contributes to the induction of apoptosis in response to DNA damage. Phosphorylates NFATC1, and thereby inhibits its accumulation in the nucleus and its transcription factor activity. Phosphorylates EIF2B5 at 'Ser-544', enabling its subsequent phosphorylation and inhibition by GSK3B. Likewise, phosphorylation of NFATC1, CRMP2/DPYSL2 and CRMP4/DPYSL3 promotes their subsequent phosphorylation by GSK3B. May play a general role in the priming of GSK3 substrates. Inactivates GYS1 by phosphorylation at 'Ser-641', and potentially also a second phosphorylation site, thus regulating glycogen synthesis. Mediates EDVP E3 ligase complex formation and is required for the phosphorylation and subsequent degradation of KATNA1. Phosphorylates TERT at 'Ser-457', promoting TERT ubiquitination by the EDVP complex. Phosphorylates SIAH2, and thereby increases its ubiquitin ligase activity. Promotes the proteasomal degradation of MYC and JUN, and thereby regulates progress through the mitotic cell cycle and cell proliferation. Promotes proteasomal degradation of GLI2 and GLI3, and thereby plays a role in smoothened and sonic hedgehog signaling. Plays a role in cytoskeleton organization and neurite outgrowth via its phosphorylation of DCX and DPYSL2. Phosphorylates CRMP2/DPYSL2, CRMP4/DPYSL3, DCX, EIF2B5, EIF4EBP1, GLI2, GLI3, GYS1, JUN, MDM2, MYC, NFATC1, p53/TP53, TAU/MAPT and KATNA1. Can phosphorylate histone H1, histone H3 and histone H2B (in vitro). Can phosphorylate CARHSP1 (in vitro).

Cellular Location

Cytoplasm. Nucleus. Note=Translocates into the nucleus following DNA damage

Tissue Location

Testis, after the onset of spermatogenesis.


DYRK2 Antibody (N-term) - Protocols

Provided below are standard protocols that you may find useful for product applications.


- Western Blot
- Blocking Peptides
- Dot Blot
- Immunohistochemistry
- Immunofluorescence
- Immunoprecipitation
- Flow Cytomety
- Cell Culture

DYRK2 Antibody (N-term) - Images






Western blot analysis of lysates from CEM, Hela cell line (from left to right), using DYRK2 Antibody (P46) (Cat. #AP7534a). AP7534a was diluted at 1:1000 at each lane. A goat anti-rabbit IgG H&L(HRP) at 1:5000 dilution was used as the secondary antibody. Lysates at 35ug per lane.



The anti-DYRK2 Pab (Cat. #AP7534a) is used in Western blot to detect DYRK2 in 293 cell lysate.



DYRK2 Antibody (N-term) (Cat. #AP7534A)immunohistochemistry analysis in formalin fixed and paraffin embedded human testis tissue followed by peroxidase conjugation of the secondary antibody and DAB staining. This data demonstrates the use of DYRK2 Antibody (N-term) for immunohistochemistry. Clinical relevance has not been evaluated.



DYRK2 Antibody (N-term) - Background

DYRK2 belongs to a family of protein kinases whose members are presumed to be involved in cellular growth and/or development. The family is defined by structural similarity of their kinase domains and their capability to autophosphorylate on tyrosine residues. DYRK2 has demonstrated tyrosine autophosphorylation and catalyzed phosphorylation of histones H3 and H2B in vitro.

DYRK2 Antibody (N-term) - References

Becker, W., et al., J. Biol. Chem. 273(40):25893-25902 (1998).

DYRK2 Antibody (N-term) - Citations

- Frequent DYRK2 gene amplification in micropapillary element of lung adenocarcinoma an implication in progression in EGFR-mutated lung adenocarcinoma
- The stress-responsive kinase DYRK2 activates heat shock factor 1 promoting resistance to proteotoxic stress
- <u>Downregulation of dual-specificity tyrosine-regulated kinase 2 promotes tumor cell proliferation and invasion by enhancing cyclin-dependent kinase 14 expression in breast cancer.</u>
- Impairment of DYRK2 augments stem-like traits by promoting KLF4 expression in breast cancer.
- The Expression of the Ubiquitin Ligase SIAH2 (Seven In Absentia Homolog 2) Is Increased in Human Lung Cancer.
- <u>Dual-specificity tyrosine phosphorylation-regulated kinase 2 (DYRK2) as a novel marker in T1 high-grade and T2 bladder cancer patients receiving neoadjuvant chemotherapy: DYRK2 is associated with survival in bladder cancer.</u>
- Downregulation of DYRK2 can be a predictor of recurrence in early stage breast cancer.
- Mutual regulation between SIAH2 and DYRK2 controls hypoxic and genotoxic signaling pathways.
- DYRK2 priming phosphorylation of c-Jun and c-Myc modulates cell cycle progression in human cancer cells.
- Expression of dual-specificity tyrosine-(Y)-phosphorylation-regulated kinase 2 (DYRK2) can be a favorable prognostic marker in pulmonary adenocarcinoma.
- DYRK2 expression may be a predictive marker for chemotherapy in non-small cell lung cancer.